Athenex, Inc.

OTCPK:ATNX.Q Stock Report

Market Cap: US$131.7k

Athenex Management

Management criteria checks 4/4

Athenex's CEO is Johnson Lau, appointed in Jan 2011, has a tenure of 12.75 years. total yearly compensation is $714.51K, comprised of 73.5% salary and 26.5% bonuses, including company stock and options. directly owns 2.99% of the company’s shares, worth $3.93K. The average tenure of the management team and the board of directors is 4.5 years and 4.9 years respectively.

Key information

Johnson Lau

Chief executive officer

US$714.5k

Total compensation

CEO salary percentage73.48%
CEO tenure12.8yrs
CEO ownership3.0%
Management average tenure4.5yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 11

Athenex prices $30M in stock and warrants offering

Athenex (NASDAQ:ATNX) plunged 23.9% down premarket after it priced its underwritten public offering of 35.3M shares and accompanying warrants at a combined public offering price of $0.75/share and accompanying warrant, pre-funded warrants to purchase up to 4.67M shares at a combined public offering price of $0.749/share and accompanying warrant. Gross proceeds are expected to be ~$30M. Offer is expected to close on Aug.15, 2022. Net proceeds was used to fund ongoing clinical development for its product candidates and for working capital and other general corporate purposes.
Seeking Alpha • Aug 05

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

The shares of Athenex Inc. (NASDAQ:ATNX) climbed ~70% on rising volumes in the post-market Thursday in reaction to reports that India's Dr. Reddy's Laboratories (RDY) and Intas Pharmaceuticals are in talks to acquire the cancer-focused biotech. The companies are competing against several mid-market healthcare-focused U.S. private equity funds to strike a deal as the biotech looks to sell a controlling stake, India's The Economic Times newspaper reported citing people with knowledge of the matter. The clinical-stage biotech is said to have named Cowen to lead a formal process to find an acquirer. "A formal process has started, and the first round of offers have come in," one of the people said. "Intas and Dr. Reddy's are the two Indian firms in the race at present. A transaction could be concluded during the current quarter." Athenex (ATNX) is the latest biotech to generate reports of buyout interest on Thursday. Before the market open, Amgen (AMGN) announced an agreement to acquire ChemoCentryx (CCXI) for $3.7B in cash.
Seeking Alpha • Jul 28

Athenex GAAP EPS, revenue misses estimates

Athenex press release (NASDAQ:ATNX): Q2 GAAP EPS of -$0.28 misses by $0.13. Revenue of $25.79M (+17.7% Y/Y) misses by $5.47M. Shares +5% PM. Athenex continues to expect product sales from continuing operations growth to be in the range of 20-25% over the prior year period.
Seeking Alpha • Jul 11

Athenex to sell its China API business for $19M

Athenex (NASDAQ:ATNX) and certain affiliates to sell all of its equity interests in its China subsidiaries, which are primarily engaged in Active Pharmaceutical Ingredient (API) manufacturing operations, to TiHe Capital Co., Ltd. for RMB 124.4 million, or ~$19M. Athenex will receive at least 70% of the proceeds at closing, followed by 20% within three months after the closing date, and the remaining balance within six months after the closing date. The proceeds will be used in part toward repaying existing debt and operating the business. The deal is subject to customary closing conditions Athenex and TiHe also plan to enter into a long-term supply agreement for the manufacture and supply of certain API products. The company continues to monetize non-core assets to extend cash runway. ATNX --3.1563845% after hours to $0.54 Source: Press Release
Seeking Alpha • Aug 31

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Athenex, Inc. is a biopharmaceutical company developing and commercializing next-generation drugs for treating various cancers. Athenex's pipeline consists of four therapeutic programs, Orascovery (P-glycoprotein pump inhibitor), Src Kinase Inhibition, Cell Therapy, and Arginine Deprivation Therapy. Athenex's lead therapeutic is Klisyri (tirbanibulin) launched in the US in Feb 2021 with an EU launch expected in 2H’21 under a partnership with Almirall. Athenex received a CRL from the FDA in Feb'21 for Oral paclitaxel + encequidar's and now Athenex is planning a new study design expected to be presented in 4Q 2021. In summary, the author projects Athenex, Inc. as a "hold".
Analysis Article • Apr 04

Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Mar 09

Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?

Some Athenex, Inc. ( NASDAQ:ATNX ) shareholders may be a little concerned to see that insider Wei Zuo recently sold a...
Analysis Article • Mar 06

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

One thing we could say about the analysts on Athenex, Inc. ( NASDAQ:ATNX ) - they aren't optimistic, having just made a...
Analysis Article • Feb 19

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Analysis Article • Jan 29

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

With the business potentially at an important milestone, we thought we'd take a closer look at Athenex, Inc.'s...

CEO Compensation Analysis

How has Johnson Lau's remuneration changed compared to Athenex's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022US$715kUS$525k

-US$98m

Sep 30 2022n/an/a

-US$178m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$198m

Dec 31 2021US$2mUS$525k

-US$158m

Sep 30 2021n/an/a

-US$132m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$144m

Dec 31 2020US$3mUS$161k

-US$142m

Sep 30 2020n/an/a

-US$118m

Jun 30 2020n/an/a

-US$116m

Mar 31 2020n/an/a

-US$108m

Dec 31 2019US$4mUS$519k

-US$123m

Sep 30 2019n/an/a

-US$129m

Jun 30 2019n/an/a

-US$141m

Mar 31 2019n/an/a

-US$145m

Dec 31 2018US$3mUS$500k

-US$117m

Sep 30 2018n/an/a

-US$119m

Jun 30 2018n/an/a

-US$96m

Mar 31 2018n/an/a

-US$97m

Dec 31 2017US$5mUS$500k

-US$131m

Sep 30 2017n/an/a

-US$143m

Jun 30 2017n/an/a

-US$144m

Mar 31 2017n/an/a

-US$118m

Dec 31 2016US$522kUS$200k

-US$88m

Compensation vs Market: Johnson's total compensation ($USD714.51K) is about average for companies of similar size in the US market ($USD740.57K).

Compensation vs Earnings: Johnson's compensation has been consistent with company performance over the past year.

CEO

Johnson Lau (63 yo)

12.8yrs
Tenure
US$714,505
Compensation

Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics.Dr. Lau serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Yiu-Nam Lau
Chairman & CEO12.8yrsUS$714.51k2.99%
$ 3.9k
Jeffrey Yordon
COO & President of Athenex Pharmaceutical Division6.7yrsUS$524.66k0.14%
$ 186.9
Daniel Lang
President of Athenex Cell Therapy2.4yrsUS$481.15k0.047%
$ 62.0
Allen Barnett
Co-Founder & President Emeritus12.8yrsno datano data
Steven Adams
Chief Accounting Officer2.2yrsUS$289.28k0.0018%
$ 2.4
Caileigh Dougherty
Director of Investor Relationsno datano datano data
Jacqueline Li
Vice President of Alliance Management & Corporate Development3.8yrsno datano data
John Matthei
Chief Human Resource Officerno datano datano data
David Cutler
Deputy Chief Medical Officer of Biologics & Cell Therapy3.8yrsno datano data
Timothy Cook
Chief Business & Commercial Officer of Proprietary Drugs5.3yrsno data0.048%
$ 62.9
Nicholas Campbell
Chief Restructuring Officerless than a yearno datano data
Li Shen
Vice President of Financial Planning & Treasury6.8yrsno datano data
4.5yrs
Average Tenure
59yo
Average Age

Experienced Management: ATNX.Q's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yiu-Nam Lau
Chairman & CEO19.9yrsUS$714.51k2.99%
$ 3.9k
John Vierling
Independent Director4.5yrsUS$42.00k0.14%
$ 187.4
Jinn Wu
Independent Director16.5yrsUS$40.86k0.40%
$ 529.0
Robert Jay Spiegel
Independent Director3.2yrsUS$46.00k0.053%
$ 69.8
Kwan-Hung Tsang
Independent Director5.3yrsUS$55.14k0.20%
$ 257.2
Jordan Kanfer
Independent Director4.5yrsUS$42.00k0.0099%
$ 13.0
Manson Fok
Director8.3yrsUS$35.71k1.28%
$ 1.7k
Stephanie Davis
Lead Independent Director4.5yrsUS$46.00k0.093%
$ 121.8
4.9yrs
Average Tenure
64.5yo
Average Age

Experienced Board: ATNX.Q's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/04 01:08
End of Day Share Price 2023/10/02 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Athenex, Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack HuDeutsche Bank
Umer RaffatEvercore ISI
Jialin ZhangICBC International Research